Background. Endothelial dysfunction contributes to accelerated atherosclerosis in chronic kidney disease (CKD). Bone marrow-derived endothelial progenitor cells (EPC) constitute an endogenous vascular repair system protecting against atherosclerosis. Smooth muscle progenitor cells (SPC) may stimulate atherosclerosis development. We hypothesized that an imbalance in EPC and SPC occurs in CKD, which may contribute to the increased cardiovascular disease (CVD) risk.
Introduction
Cardiovascular disease (CVD) is a major threat to patients with chronic kidney disease (CKD) [10] . Endothelial dysfunction and impaired endothelial regenerative capacity play a key role in the pathogenesis of CVD [9] . Bone marrow (BM)-derived endothelial progenitor cells (EPC) constitute an endogenous vascular repair system that protects against atherosclerosis development [2] . A decline in EPC availability or function may contribute to the pathogenesis of CVD [29] . The presence of cardiovascular risk factors or CVD has been related to reduced EPC levels and function in many, but not all studies [17, 28, 29, 31] . Besides differentiation towards endothelial cell phenotype, BM-derived vascular progenitors may differentiate towards smooth muscle cells and myofibroblasts in the vessel wall, participating in atherosclerosis development [22, 26] . Increased levels of these smooth muscle progenitor cells (SPC) have been observed in diabetic and in coronary artery disease (CAD) patients, which may contribute to vascular complications [20, 24] .
In kidney disease, vascular progenitor cell availability and function may be adversely affected by accumulation of toxins, including oxidative products [14] . Several studies demonstrated reduced EPC levels in patients on dialysis [4, 7] . We reported reduced EPC but unaffected SPC outgrowth in haemodialysis patients, suggesting impaired endothelial regenerative capacity, while the capacity of progenitor cells to contribute to adverse vascular remodelling is retained [30] . Interestingly, better correction of the uraemic environment increases EPC levels in end-stage kidney disease [6, 11] . In kidney transplant patients, a negative relation between EPC levels and graft dysfunction was observed [11] . Information on SPC and EPC in predialysis CKD is scarce.
We hypothesized that an imbalance between EPC and SPC is present in pre-dialysis CKD. This imbalance may result in impaired regenerative and enhanced profibrotic tendency and contribute to the increased cardiovascular risk. We determined circulating CD34 + KDR + -EPC and mononuclear cell (MNC) outgrowth towards EPC and SPC in patients with varying degrees and different causes of CKD. Paracrine effects of cultured EPC were tested in a scratch wound assay. We investigated whether progenitor cell number and function in CKD are related to cause and degree of kidney insufficiency and to endothelial dysfunction markers or history of CVD. Finally, we investigated whether changed levels of progenitor cell-mobilizing factors underlie altered EPC levels.
Materials and methods

Subjects
Patients with different stages of CKD, defined as kidney damage or estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 for ≥3 months, and no diabetes, dialysis treatment or malignancy were consecutively recruited from the nephrology outpatient clinic, University Medical Center Utrecht (UMCU), The Netherlands. Recruited patients were not allowed to have current infection. Out of 50 recruited patients, 49 were eligible for enrolment due to exclusion of one patient with increased inflammatory markers. Patients maintained their regular medication. Thirtyfive age-matched healthy subjects were recruited (colleagues, family, spouse of patient), of whom 33 were eligible to serve as controls (two controls were excluded due to multivitamin use and increased inflammatory markers). The study protocol was approved by the local ethics committee and all subjects gave informed consent. Procedures were in accordance with the Helsinki Declaration.
Biochemical parameters were measured in fasting blood samples using standard procedures. Albuminuria (immunoturbidimetric assay) and albumin-to-creatinine ratio were assessed in morning urinary specimen. The MDRD formula [18] was used to calculate the eGFR.
Patients were divided into groups with an atherosclerotic or nonatherosclerotic cause of CKD as diagnosed by the patient's nephrologist. Presence of a history of CVD was defined as myocardial infarction, angina pectoris, cerebrovascular accident, transient ischaemic attack, peripheral artery disease or revascularization diagnosed in medical history.
Endothelial dysfunction
As a surrogate marker of subclinical atherosclerosis, arterial stiffness was assessed by measuring augmentation index (Aix) and pulse wave velocity (PWV) using the SphygmoCor2000 system according to the manufacturer's instructions. Three good quality data runs for each measurement were averaged.
Markers reflecting endothelial activation and/or injury [E-selectin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), thrombomodulin] were measured using commercially available ELISA (R&D Systems, Minneapolis, USA; Diaclone, Stamford, USA).
Circulating EPC
EDTA blood was collected from fasting subjects. One hundred microlitres of blood was incubated with anti-CD34-FITC, anti-CD45-PE-Cy7 (BD Pharmingen, San Diego, USA) and anti-KDR-PE (R&D Systems) antibodies. Erythrocytes were lysed and cells were analyzed by flow cytometry (Beckman Coulter, Fullerton, USA). EPC were identif ied as CD34 + KDR + -cells in the lymphocyte region of the forward/sideward scatter plot and quantified relative to 10 5 granulocytes, identified as CD45 + -cells with a typical granulocyte distribution. Measurements were performed in duplicate and results were averaged. Isotype-stained samples served as negative controls.
Outgrowth of EPC and SPC in culture EPC and SPC outgrowth from MNC was assessed as previously described [30] . MNC were isolated from blood samples using Ficoll density gradient separation (Histopaque 1077, Sigma, St. Louis, USA). To evaluate EPC outgrowth, 10 7 MNC per well were seeded on a human fibronectin (Sigma)-coated six-well plate in EGM-2 (Cambrex, Walkersville, USA), supplemented with accompanying aliquots, 20% foetal calf serum (Invitrogen, Carlsbad, California), 100 ng/mL recombinant VEGF-165 (R&D Systems) and antibiotics. Medium was changed after 4 days. After 7 days, cultured EPC in selected wells were placed on serum-free medium (EBM-2 with hEGF, hydrocortisone, GA-1000, R 3 -IGF-1, ascorbic acid, heparin and antibiotics) overnight. Conditioned medium was stored for functional experiments. Cultured EPC were detached by trypsin and cell scraping and automatically counted using a haemocytometer.
For assessment of SPC outgrowth, 5 × 10 6 MNC per well were seeded on six-well plates coated with human fibronectin and cultured in lowglucose DMEM supplemented with 20% foetal calf serum, L-glutamine (Invitrogen), 0.5 μl/mL PDGF (R&D Systems) and antibiotics. Medium was changed after 4 days. At Day 8, cultured SPC were detached by trypsin and cell scraping and automatically counted using a haemocytometer.
In vitro scratch wound assay
The potential of EPC outgrowth to excrete paracrine factors that stimulate endothelial cell migration was assessed by in vitro scratch wound assay [19] . A mechanical scratch was created with a pipette tip in a confluent monolayer of human microvascular endothelial cells (HMECs; Centers for Disease Control and Prevention, Atlanta, USA). After washing with PBS, EPC outgrowth conditioned medium was placed on the cells. Serum-free EPC medium served as negative control. Reference lines were made on the bottom of the wells to obtain exactly the same field during image acquisition. The scratched area was photographed using a light microscope at the start and after 6 h of incubation (37°C). The extent of closure after 6 h was determined relative to the starting width of the scratch (Image-Pro plus software, Media Cybernetics 3.0). Each sample was measured in two wells and two picture fields per well were examined. Results were averaged for analysis.
VEGF/SDF-1α plasma measurements
Plasma vascular endothelial growth factor (VEGF) and stromal cellderived factor-1α (SDF-1α) levels were measured by ELISA (R&D Systems). All samples were measured in duplicate and averaged for analysis.
Statistical analysis
Data analysis was performed using SPSS 15.0 for Windows. The Kolmogorov-Smirnov statistical test was used to explore whether data were normally distributed. Data are expressed as mean ± standard deviation for parametric data and as median (minimum-maximum) for nonparametric data. Group differences were analyzed by Student's t-test or Mann-Whitney test. Multiple group comparisons were performed using ANOVA with LSD post hoc testing for which non-parametric data were log-transformed. Fisher's exact test was used to analyze whether proportions of categories varied by group. Correlations were measured by Pearson's or Spearman's correlation coefficient where appropriate. P-value <0.05 was considered statistically significant.
Results
Patient characteristics
Patients with different stages of CKD were included (eGFR 60-69: n = 7; eGFR 45-59: n = 13; eGFR 30-44: n = 12; eGFR 15-29: n = 7; eGFR <15: n = 10). Patient characteristics are listed in Table 1 .
Vascular progenitor cell levels in CKD
EPC outgrowth was lower in CKD vs controls ( Figure 1A Degree of kidney dysfunction. Reduced EPC outgrowth was already observed in mild to moderate CKD [8 (2-22) in patients with eGFR >30 mL/min/1.73 m 2 vs 12 (1-38) cells/10 3 MNC in controls, P = 0.021]. A further decline in kidney function was not related to cultured EPC numbers (r = 0.133, P = 0.272; Figure 2A ). Among CKD patients, no correlations were found for eGFR with EPC migration capacity (r = 0.161, P = 0.304) or circulating CD34 + KDR + -EPC levels (r = −0.138, P = 0.351; Figure 2B ). A significant negative association was found between SPC outgrowth and eGFR (r = −0.397, P = 0.008). Plasma urea, microalbuminuria and total albumin-to-creatinine ratio were also not associated with any of the progenitor cell measures (data not shown). Endothelial dysfunction. Aix, thrombomodulin and VCAM-1 were higher in CKD compared to controls and increased with declining eGFR (Table 2) . A significant association was observed between cultured EPC and Aix (r = −0.37, P = 0.013). The migratory capacity of HMECs was also lower in conditioned EPC medium from patients with increased VCAM-1 (r = −0.343, P = 0.023) and E-selectin levels (r = −0.262, P = 0.075). Higher SPC outgrowth was associated with higher ICAM-1 levels in CKD (r = 0.463, P = 0.006). Values are n (number) (%), mean ± SD or median (minimum-maximum). * P-value <0.05 compared to healthy controls. Mainly glomerulonephritis, polycystic kidney disease, nephrolithiasis, lithium-induced, membranous glomerulopathy.
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VEGF and SDF-1α in CKD patients VEGF and SDF-1α levels were increased in CKD compared to controls (125 ± 29 vs 28 ± 24 pg/mL, P = 0.003 and 3.2 ± 0.7 vs 2.6 ± 0.6 ng/mL, P < 0.001, respectively).
VEGF and SDF-1α levels were related with degree of kidney dysfunction (r = −0.48, P < 0.001 and r = −0.72, P < 0.001, respectively) and presence of endothelial dysfunction (Table 3) . EPC outgrowth and migratory capacity Fig. 2 . Correlation of EPC outgrowth levels with the degree of kidney dysfunction: cultured EPC levels (A) and circulating CD34 + KDR + -EPC (B) are already decreased in CKD patients with mild kidney dysfunction; a further decline in eGFR was not correlated with EPC levels. Fig. 1 . EPC levels and function in CKD patients compared to healthy controls: CKD patients show decreased EPC outgrowth (A), whereas SPC outgrowth was not significantly different (B); circulating EPC numbers are lower in CKD patients compared to healthy controls (C); scratch width at start (D; upper picture) and closure after 6 h incubation (D; lower picture) was measured, adjusted for image acquisition variance with help of the blue marker lines (see colour figure in online supplement); migratory capacity of HMECs in conditioned EPC medium from patients was not significantly decreased compared to healthy controls (D; graph).
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were most reduced in subjects with the highest VEGF levels (r = −0.288, P = 0.028 and r = −0.418, P = 0.007, respectively).
Discussion
Our study shows that pre-dialysis CKD patients on regular medical therapy have lower levels of circulating EPC and reduced EPC outgrowth compared to healthy controls. This reduction in EPC did not depend on cause or degree of kidney dysfunction. SPC outgrowth gradually increased with declining kidney function in CKD. These data suggest that, in a uraemic environment, EPC-mediated endogenous vascular regeneration may be impaired, whereas SPC-mediated development of atherosclerosis may be enhanced. Reduction in EPC levels could not be attributed to reduced VEGF or SDF-1α levels. Few studies have yet reported on EPC and SPC levels in CKD. Previous studies demonstrated reduced EPC levels and function as well as an imbalance between EPC and SPC in haemodialysis patients [4, 7, 30] . These data suggested an adverse effect of uraemia on vascular progenitor cells. However, dialysis sessions, in themselves, were related to reduced EPC levels, and the overall worse condition and (cardiovascular) comorbidity of dialysis patients may have influenced these results. Several studies suggested that reduction of uraemia by kidney transplantation improved EPC numbers and function [11, 13] . Furthermore, EPC levels, were related to graft function by some [11, 13] , but not others [23] . The effects of immunosuppressive therapy and former exposure to long-term dialysis treatment complicate interpretation of these findings. Surdacki et al. [25] studied a very specific population of patients with stable angina and severe angiographic CAD with strict criteria on medication use and comorbidity. They found lower CD34 + KDR + -EPC counts in patients with impaired kidney function within their selected population. In this study, patients in the lower eGFR groups also had more severe CAD which may have influenced the re- Fig. 3 . Circulating EPC levels in CKD patients with a history of CVD: circulating EPC levels were lower in CKD compared to healthy controls, which was more pronounced in patients with a history of CVD; data were log-transformed and P-values are given with respect to healthy controls. Values are presented as mean ± SD or median (minimum-maximum); correlation values (r) are shown as Pearson's or Spearman's correlation where appropriate. * P-value <0.05. a P-value for univariate analysis between marker levels in CKD patients and healthy controls. b P-value for correlation analysis between marker levels and kidney function.
Progenitor cells in chronic kidney disease 1879 sults. No EPC or SPC outgrowth numbers were reported in this study. Krenning et al. [16] reported lower numbers of CD34 + -haematopoietic stem cells in CKD patients more comparable to our population, but did not assess CD34 + KDR + -EPC levels, the type of EPC that was predictive for cardiovascular events in CAD patients [29] . They observed decreased endothelial outgrowth of MNC obtained from CKD patients on PCLdiUPy biomaterial and suggested a limitation for use of EPC derived from CKD patients in regenerative medicine. Although we did not observe significantly lower CD34 + -cells, we found reduced numbers of circulating CD34 + KDR + -EPC. This reduction was even present in mild CKD. Furthermore, our data indicate that, already in mild kidney dysfunction, a ∼25% decrease in EPC outgrowth on fibronectin-coated plates o c c u r s . T h e s e f i n d i n g s a r e i m p o r t a n t a s l ow CD34 + KDR + -EPC numbers and reduced EPC outgrowth using comparable culture methods were previously associated with increased cardiovascular risks [29] . Our observation, that a small decline in eGFR compared to our controls was associated with low EPC levels, may indicate that minor loss of kidney function relates to reduced EPC levels. Exact indication of the tipping point at which progenitor cell changes occur would require larger sample size. Of note, we may have underestimated eGFR in our controls as the MDRD formula is less accurate in healthy populations. We observed preserved SPC levels together with diminished EPC in CKD. Together, our findings indicate that uraemia not only has a negative influence on progenitor cells in end-stage kidney disease [30] , but also in earlier stages of kidney dysfunction. This may contribute to the accelerated atherosclerosis in CKD patients. Additionally, these alterations in vascular progenitor cell levels may advance progression of CKD as it has been reported that EPC contribute to glomerular endothelial repair [21] , whereas SPC may enhance glomerulosclerosis [8] .
We did not find a correlation between EPC levels and the degree of kidney dysfunction within our CKD group. We investigated progenitor cells in patients on regular medication, which provides valuable information, since CKD patients are at increased risk for CVD despite current medical treatment regimens. However, medication use could have influenced the relation between EPC levels and the degree of kidney dysfunction. Erythropoietin is a well-known EPC-mobilizing agent [4] . Excluding erythropoietin-treated patients from our analysis did not influence our results; however, we cannot exclude that selection bias of other medication could have influenced our results. Indeed, we demonstrated lower CD34 + KDR + -EPC levels in patients on statin or RAS blockade, which have previously been reported to increase EPC numbers [3, 27] . Possibly, EPC levels were even lower in the absence of medical treatment. In addition, we cannot exclude that our patients with severe CKD were in a relatively good condition.
We did not find a relation between the underlying cause of CKD and levels of progenitor cells. Previous studies in dialysis patients [7, 30] also did not detect differences in EPC level when comparing patients with diabetic and non-diabetic causes. Since atherosclerosis may underlie, but also may result from CKD, absolute separation of atherosclerotic and non-atherosclerotic CKD remains difficult. Of note, most of the non-atherosclerotic CKD patients suffered from cystic kidney disease, recurrent nephrolithiasis or lithiuminduced CKD. These data suggest that the effect of other factors than CKD degree or cause is dominant in the determination of EPC recruitment, mobilization and function.
Several studies have shown that the presence of cardiovascular risk factors or CVD is an important determinant of reduced EPC levels [28, 29] . However, others did not observe such inverse relations or even reported a positive relation between EPC number and vascular risk factors [17, 31] , which could reflect a protective compensatory response to the vascular risk burden. We found that CKD patients with a history of CVD had reduced CD34 + KDR + -EPC numbers compared to patients without such history. This is in line with previously reported associations between EPC levels and history of CVD in patients on peritoneal dialysis [23] . Furthermore, EPC outgrowth and function were negatively associated with endothelial dysfunction parameters in our subjects and increased levels of outgrowth SPC were found in patients with higher endothelial dysfunction markers. The combination of endothelial dysfunction with lack of a compensatory response but even reduced EPC levels, reflecting impaired endothelial repair, and enhanced numbers of SPC may accelerate atherosclerosis in CKD. Our population consisted of patients under current treatment regimen with minimal exclusion criteria, thus representing the CKD population, but heterogeneous in its composition, comorbidity, medication and other influencing factors. An important limitation of our study is that influences of reduced eGFR, (cardiovascular) comorbidity and medication on EPC and SPC cannot be fully separated from each other. However, cardiovascular risk factors can be the cause and result of renal insufficiency, which complicates such discerning analyses. In addition, cardiovascular risk indicators may manifest differently in CKD patients and may not correlate with CVD events as in subjects without CKD [15] .
The cross-sectional nature of our study does not allow definitive conclusions on the mechanism underlying diminished EPC levels in CKD. We investigated whether a defect of EPC-mobilizing factors in response to endothelial injury could explain the reduced EPC levels in CKD. We found that, with progression of CKD and endothelial dysfunction, important stimuli SDF-1α and VEGF gradually increased, while EPC levels remained low. Moreover, EPC outgrowth was most reduced in subjects with highest VEGF levels. Low circulating EPC pools could result from increased homing of EPC to injured tissue mediated by SDF-1α and VEGF [31] . SDF-1α and VEGF may be accumulated due to reduced renal clearance, which may result in continuous stimuli and eventually resistance of EPC. Alternatively, there could be a common underlying mechanism for endothelial dysfunction and impaired EPC mobilization. Impaired nitric oxide (NO) availability [5] in CKD may underlie endothelial dysfunction and impaired EPC mobilization despite the upregulation of SDF-1α and VEGF, as both processes are NO-dependent [1] . Increased SDF-1α levels together with endothelial NO synthase deficiency can also result in enhanced SPC levels [32] , thereby contributing to neointimal lesion formation. We used eGFR calculated by the MDRD equation to correlate the degree of uraemia to EPC levels. The eGFR represents the collection of a whole variety of accumulated uraemic toxins. Whereas a decrease in eGFR is associated with an increased risk for cardiovascular events [12] , it is not known which uraemic toxin importantly influences EPC availability and function. Plasma urea concentration, microalbuminuria and total albumin-to-creatinine ratio as other markers for kidney function were also not associated with EPC levels in our study. More insight in toxic substances influencing EPC in CKD may provide a more specific uraemic marker set to correlate with EPC levels to monitor and predict CVD risk.
Conclusion
In conclusion, CKD patients on regular medication have lower circulating EPC levels and reduced EPC outgrowth already in mild CKD, whereas outgrowth towards SPC is increased with decline in kidney function. Moreover, lower EPC numbers were found in patients with a history of CVD and endothelial dysfunction. EPC reduction could not be attributed to impaired SDF-1α and VEGF levels.
